FN Media Group Presents GlobalInvestmentDaily.com Market Commentary
The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global healthcare industry, America is definitely not first. Americans are fed up, and a digital revolution that goes way beyond telemedicine is the only thing that will restore control. Mentioned in today’s commentary includes: Sage Therapeutics, Inc. (NASDAQ: SAGE), Cassava Sciences, Inc. (NASDAQ: SAVA), COMPASS Pathways plc (NASDAQ: CMPS), Neuronetics, Inc. (NASDAQ: STIM), Acadia Healthcare Company, Inc. (NASDAQ: ACHC).
Fixing it is a highly disruptive, multi-trillion-dollar opportunity. Telemedicine, or ‘Telehealth’, will soar from $42 billion in 2018 to $400 billion in 2026. Healthcare IT alone will be worth $390 billion by 2024. But the biggest disruptor of them all may be medical apps. And the advantage just might go to a Canadian company with perhaps the most sophisticated AI the healthcare sector has ever seen …
Because it was developed by, and trained by, a huge team of doctors and medical experts from all over the world. Now, it’s about to launch in North America. And plans to then go global. City by city.
The company is Treatment.com International Inc. (TRUE; TREIF)and the world has never seen anything like global library of medicine, nor CARA, the new doctor-developed AI that could be set to revolutionize the $11 trillion healthcare industry
CARA is personalized in every way. CARA, Treatment’s Digital Assistant assesses symptoms based on your actual information; CARA helps you to diagnose health problems, makes recommendations, tracks and monitors your symptoms and follows up with your healthcare every step of the way. From cradle to grave, CARA helps you and your entire family (including caregivers) manage healthcare. The technology is 100% proprietary and it’s ready to win over a massive consumer base that is begging for a healthcare revolution.
AI Healthcare Is Here
Medical apps are tapped to be the fastest-growing IT healthcare segment, with consumers starving for better services that they can actually control and understand. We’re just at the beginning of a complete revolution in the healthcare industry, and Treatment.com is the first to truly attempt to empower the consumer with AI that thinks like a doctor because it was trained by real doctors over the past six years. The team behind it has a near perfect track record in building and scaling IT infrastructure, particularly in the healthcare sector, with major rewards for investors.
For the past 6 years, a team of over 40 global world-class medical experts have been working to build the AI infrastructure for CARA and Treatment.com International Inc. The AI is already so sophisticated it’s been licensed by the University of Minnesota Medical School to teach and test medical students.
The Rush For Healthcare Solutions Is Heating Up
UK-based Babylon Health, a telehealth startup, is set to go public in the U.S. via a $4.2-billion SPAC deal. Big money should be looking for better deals than this, though. Deals that prioritize and emphasize artificial intelligence.
That’s what makes Babylon less attractive than it could be, says Treatment.com’s Dr. Keven Peterson. “Babylon has struggled to provide an effective [AI powered] clinical decision support product. Their revenues are based on their clinical telemedicine, which uses the weakness of their app to draw people into the telemedicine interaction,” Peterson said, commenting on the $4.2-billion SPAC deal.
Treatment.com International offers digital capabilities powered by AI that are stronger than anything thrown at the market to date.
Medical apps powered by AI are poised to explode precisely because the AI brings everything together, intelligently. Americans are desperate for healthcare clarity; Treatment.comgives it to them. Googling symptoms does not.
CARA isn’t a game of googling symptoms and coming up with the most-searched piece of potential, anxiety-causing misinformation. CARA uses your medical records and the power of sophisticated AI trained by doctors to assess your symptoms and get you the care that you need, seamlessly.
All of this makes the underlying, 100% owned proprietary IP something that should have investor interest piqued. Keep this name on your radar as Treatment.com International (TRUE; TREIF)plans to launch it’s ground-breaking APP – ‘CARA’ – powered by the most comprehensive AI in the industry, before the end of this year.
The Healthcare Industry Is Ripe For Disruption
Sage Therapeutics (SAGE) is an incredible example of a company using its immense resources and knowhow to tackle the growing health crisis in the United States and abroad. With a focus on exciting new ways to treat mental health disorders, the company released the only FDA-approved treatment for post-partum depression.
Dr. Jeffrey Cohen founded Sage Therapeutics in 2003 with a mission to discover and develop life-saving medicines for rare diseases. The company has gone on create treatments that have been approved all around the world, including Pompe disease, Sanfilippo syndrome type A (a form of although largely affecting children), Fabry disease as well Gaucher Disease which can be hereditary or caused by environmental factors such food intolerance issues like gluten sensitivity among others.
Cassava Sciences (SAVA) is a clinical-stage biopharmaceutical company focused on neurosciences. They are committed to advancing neuroscience research and developing novel therapies for patients with brain disorders. The founders of Cassava Sciences have an extensive background in both biotechnology and the pharmaceutical industry, which gives them the expertise needed to lead the company into its next phase of growth.
Cassava Sciences was founded by two scientists who worked together at Pfizer Pharmaceuticals for over 20 years before they left the company in 2015 to start their own biotech startup, one that would focus on solving some of medicine’s most difficult problems. Since then, they’ve recruited a team of likeminded individuals with deep scientific experience, as well as key partnerships with leading universities around the world.
COMPASS Pathways plc (CMPS) COMP360 solution has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. COMPASS’ meticulous approach to psilocybin treatments is important because, while legalization may look imminent, there’s still a long road ahead for this relatively new medicine.
CEO George Goldsmith explained. “There simply isn’t yet enough evidence of safety and efficacy of psilocybin therapy, which is why we’re doing our trials,” adding “the review and approval to regulatory agencies is really the best way ensure the safety, efficacy and quality of any medicine or therapy.”
Neuronetics, Inc. (STIM) is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company’s first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Neuronetics’ TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location.”
Acadia Healthcare Company, Inc. (ACHC) is a company that provides healthcare services in the United States. The company offers medical management for post-acute care and rehabilitation needs of patients after they have been discharged from hospital settings or skilled nursing facilities.
Acadia Healthcare also offers a wide range of behavioral health and addiction services to its patients through the use of evidence-based treatment methods. The company is primarily focused on providing a continuum of care for individuals in need with mental health and substance abuse related issues by developing personalized treatment plans that are designed to meet the specific needs of each individual they serve, while also providing support for family members or friends who may be involved in their recovery process.
By. William Thomas
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.
